Saint-Priest, France, September 18, 2019 – 8h00 (CET) – Biom’up SA (the “Company”), specializing in surgical hemostasis, today announced that Patrice Ferrand was appointed CEO, replacing Dr. Jan Ohrstrom. Dr. Ohrstrom, who was appointed CEO in May of this year, remains Chairman of the Board, a role in which he has served for the Company since 2015. Mr. Ferrand will also be appointed Chairman of the Company’s U.S. subsidiary, Biom’up USA, Inc.
- Veteran MedTech executive Patrice Ferrand is appointed CEO
- Experienced pharmaceutical and biotech industry executive Evelyne Nguyen is appointed Group CFO
- Dr. Jan Ohrstrom continues his tenure as Chairman of the Board
- Current CCO for the United States George Makhoul is appointed CEO of Biom’up USA, Inc.
With more than 30 years of experience overall and close to 16 years of general management experience in the MedTech industry, Patrice Ferrand is a veteran leader of commercial-stage organizations. Before joining Biom’up, Mr. Ferrand was CEO at Unilabs France, a leading provider of diagnostics services in Europe and Latin America. Prior to that, for more than 11 years he was General Manager of France & Benelux for Mölnlycke Health Care, a major provider of single-use surgical and wound care products.
Dr. Jan Ohrstrom commented: “The Board of Directors and executive team join me in welcoming Patrice Ferrand at Biom’up. Patrice is a deeply experienced leader of large, international, MedTech organizations and, in particular, of surgical product providers. He adds extraordinary depth to the management team and with the ideal skill set needed to complete its transformation from an R&D and clinical development company to a fully-fledged, scalable commercial-stage enterprise. I have enjoyed being the interim CEO of Biom’up for the past four months and look forward to working closely with Patrice to help him transition into the Company. The management team and the Board all look forward to working with him in the continued execution of the Biom’up strategy. I’m also happy to reiterate the full year 2019 global revenue guidance range of €4.0-4.5 million for HEMOBLAST Bellows that the Company provided this past May. An investor day will be held by year-end.”
Patrice Ferrand said: “After the successful approval of its product in 2017 and through the scaling up of manufacturing and commercial operations in 2018, Biom’up has built an enviable early lead in the competitive hemostat market, both in the US and Europe. I am excited and honoured to be entrusted with its leadership at such an important point in the life of the Company.”
The Company also announced the appointment of Evelyne Nguyen as Group CFO, Mrs. Nguyen’s predecessor leaving at the end of September to ensure a smooth transition of responsibilities.
Evelyne Nguyen has more than 30 years of international experience in financial and strategic roles, including 20 years in the pharmaceutical and biotech industry. Before joining Biom’up, Mrs. Nguyen held several senior positions at Bristol Myers Squibb and Laboratoire Français du Fractionnement et des Biotechnologies (LFB). At LFB, she strengthened Finance, led a number of significant acquisitions and successfully managed cross-border strategic alliances and business development projects. She also brings to Biom’up strong experience in strategic transactions and financing for companies in the Life Sciences domains.
Lastly, Biom’up announced that the current CCO for the United States, George Makhoul, is appointed CEO of Biom’up USA, Inc., the Company’s U.S. subsidiary. Mr. Makhoul, who joined the Group last January, has a long track record of success in commercializing medical products to hospitals and surgeons over the past 16 years combined with deep knowledge of the US hemostasis market. Under his supervision, the Company strengthened its presence in the United States and enabled the launch of its flagship product, HEMOBLAST™ Bellows, in a highly competitive market.
Download the press release